Capital Access Window
Sareum Holdings plc announced its intention to undertake an equity capital raise using AIM's new Capital Access Window rule to fund its lead clinical program, SDC-1801. The trading of Sareum's shares on AIM will be temporarily paused from 7:30 am BST today until further announcements detail the results of the proposed fundraise, which aims to advance SDC-1801 towards its next key clinical inflection point.
Select text to share a quote on X · sign in to keep highlights & notes in your SAR notes
Cambridge, UK, 8 October 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, today, announces its intention to utilise AIM's new Capital Access Window rule in connection with a proposed equity capital raise (the "Proposed Fundraise").
Intention to undertake an equity capital raise
The Company is undertaking the Proposed Fundraise to provide funding to advance the Company’s lead clinical programme, SDC-1801, towards its next key clinical inflection point.
Capital Access Window
Following the updates to the AIM Rules for Companies announced in August 2026, to support the Proposed Fundraise, the Company will enter a Capital Access Window with effect from 7.30am BST today. This is a voluntary temporary pause in the trading of the Company's shares on AIM to make it easier to reach a broader range of investors, and to provide pricing stability during a fundraise. The Capital Access Window will remain in place until a further announcement is made detailing the results of the Proposed Fundraise.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.